To include your compound in the COVID-19 Resource Center, submit it here.

VicOryx: Phase I started

Oryx began the open-label, German Phase I VICORYX-2 trial to evaluate 100 ug subcutaneous VicOryx with the

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE